SubsidieMeestersA microRNA-regulated cell death-inducing gene therapy for T-cell Acute Lymphoblastic Leukemia
The project aims to develop a targeted gene therapy system (miRToTALL) for T-cell acute lymphoblastic leukemia, enhancing treatment efficacy and safety while enabling precision medicine for various cancers.
Projectdetails
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Although outcomes have improved throughout the years with the use of combined chemotherapy, the aggressive regimens required for treatment efficacy often lead to significant short- and long-term side effects.
Relapse and Prognosis
Moreover, a significant fraction of T-ALL patients relapse, which has an extremely poor prognosis.
Project Goals
The current project aligns with the core goal of our ERC Consolidator Grant IL7sigNETure (CoG-648455) to generate new targeted therapies for improved treatment of T-ALL. We aim to develop a gene therapy cell death-inducing system (miRTo) that uses cell-endogenous microRNAs to regulate the expression of a cell death-inducing gene specifically in T-ALL cells (miRToTALL).
Innovative Strategy
While our innovative strategy has the potential to treat T-ALL patients more effectively and safely, it also displays market potential that extends well beyond T-ALL. This is because our technology is designed so that it can be adapted to the disease of choice or to particular disease subtypes through simple modifications. This adaptability makes it ideal for precision medicine in:
- T-ALL
- Other cancers
- Other indications in which patients may benefit from the targeted delivery of a therapeutic gene
Project Development
Our project will build upon the preliminary data that we have already generated and make use of our models and expertise in the molecular and cellular biology of T-ALL. This will provide preclinical validation of miRToTALL, laying the ground for a spin-off that will fully explore the miRTo technology platform.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2022 |
| Einddatum | 31-5-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINEpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Polyclonal anti-tumor immunity by engineered human T cellsThis project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes. | ERC STG | € 1.812.500 | 2022 | Details |
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironmentCAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies. | EIC Pathfinder | € 2.733.931 | 2023 | Details |
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemiaThe project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes. | EIC Transition | € 2.497.500 | 2023 | Details |
Improving CAR-T cell therapies through AAV-mediated genetic engineeringThis project aims to develop in vivo gene-targeted CAR-T cell therapies using evolved AAV for T cell delivery and Cas9 editing, ultimately translating findings to human clinical trials. | ERC STG | € 1.503.155 | 2025 | Details |
Polyclonal anti-tumor immunity by engineered human T cells
This project aims to enhance adoptive T cell therapies for solid tumors by engineering TCR sensitivity and safety, creating robust, antigen-agnostic immune responses to improve patient outcomes.
CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment
CAR T-REX aims to enhance CAR T cell efficacy against solid tumors by integrating auto-regulated genetic circuits to prevent exhaustion, using advanced gene editing and delivery technologies.
Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia
The project aims to develop a cost-effective immunotherapy for R/R T-ALL by dual targeting specific antigens using scalable, off-the-shelf CORD-GDT cells to improve patient outcomes.
Improving CAR-T cell therapies through AAV-mediated genetic engineering
This project aims to develop in vivo gene-targeted CAR-T cell therapies using evolved AAV for T cell delivery and Cas9 editing, ultimately translating findings to human clinical trials.